HIF prolyl-hydroxylase inhibitor
Drug class
Roxadustat, the first marketed HIF prolyl-hydroxylase inhibitor
Class identifiers
ATC codeB03X
Mechanism of actionEnzyme inhibitor
Biological targetHIF prolyl-hydroxylase
Legal status
In Wikidata

Not to be confused with Factor Inhibiting HIF Asparaginyl Hydroxylase Inhibitors

Hypoxia-inducible factor prolyl hydroxylase Inhibitors (HIF-PHIs) also known as hypoxia-inducible factor stabilizers (HIF stabilizers) are a novel class of drugs that act by inhibiting hypoxia-inducible factor-proline dioxygenase (HIF prolyl-hydroxylase) which is responsible for breaking down the hypoxia-inducible factor (HIF) under conditions of normal oxygen concentrations.

As of 2023, Vadadustat, Daprodustat, and Roxadustat are the most studied HIF-PHIs with highest number of phase III & Phase IV patient data for chronic kidney disease.[1][2] All the three drug are available in Japan, while Vadadustat & Daprodustat is under EU regulatory review for potential approval in 2023. US FDA approved Daprodustat in early 2023 after a positive adcom for favorable benefit-risk ratio, while Vadadustat is awaiting an even-handed response to its formal dispute resolution appeal, considering recent FDA approval of Daprodustat.[3]

Outside of chronic kidney disease, Akebia Therapeutics has reported initial findings from its phase II study evaluating Vadadustat for ARDS in Covid-19 patients.[4] Based on the results Akebia Therapeutics has decided to move forward with a phase III study in broader ARDS patients.[5]

The rights to Vadadustat is held by Akebia Therapeutics in partnership with CSL Vifor, Roxadustat by Fibrogen in partnership with Astellas, and Daprodustat has been internally developed by GSK.[6][7]

Examples

See also

References

  1. ↑ Chen, Dinghua; Niu, Yue; Liu, Fei; Yang, Yue; Wang, Xue; Li, Ping; Chen, Xiangmei (2022-12-29). "Safety of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Dialysis Patients: A Systematic Review and Network Meta-Analysis". Authorea Preprints. doi:10.22541/au.167229660.07194141 (inactive 1 August 2023).{{cite journal}}: CS1 maint: DOI inactive as of August 2023 (link)
  2. ↑ Zheng, Qiyan; Wang, Yahui; Yang, Huisheng; Sun, Luying; Zhang, Pingna; Zhang, Xueqin; Guo, Jing; Liu, Yu Ning; Liu, Wei Jing (2022-11-15). "Cardiac and Kidney Adverse Effects of HIF Prolyl-Hydroxylase Inhibitors for Anemia in Patients With CKD Not Receiving Dialysis: A Systematic Review and Meta-analysis". American Journal of Kidney Diseases. 81 (4): 434–445.e1. doi:10.1053/j.ajkd.2022.09.014. ISSN 0272-6386. PMID 36396085. S2CID 253570576.
  3. ↑ "HIF-PHI-delity? As FDA spins new tune in CKD anemia with GSK nod, others in class may hope to play along | BioWorld". www.bioworld.com. Retrieved 2023-02-15.
  4. ↑ Therapeutics, Akebia. "Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT)". www.prnewswire.com (Press release). Retrieved 2023-02-15.
  5. ↑ Transcripts, S. A. (2022-11-03). "Akebia Therapeutics, Inc. (AKBA) Q3 2022 Earnings Call Transcript | Seeking Alpha". seekingalpha.com. Retrieved 2023-02-15.
  6. ↑ "vadadustat". CSL Vifor. Retrieved 2023-02-15.
  7. ↑ "Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease". Astellas Pharma US, Inc. | News Room. Retrieved 2023-02-15.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.